Diversified Healthcare Trust stock
DHCNASDAQReal EstateISIN US25525P1075
32Score 32 out of 100, Weak
Price and trend
38 / 100
Price history
+60% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.1% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 34).
The price is 24% below its 52-week high. Largest decline in 20 years: 98% (May 2013 to December 2022).
Chart figures for advanced users
- SMA 50$7.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.85
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)34
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.45
- The lowest closing price of the last twelve months.
- Resistance$9.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Diversified Healthcare Trust belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $1.77B, is number 12 of 18 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.54B (up 2.8% year on year) and a loss of $285.89M.
- For fiscal 2026, analysts expect on average revenue of $1.47B (down 4.2%) and adjusted earnings per share of −$0.62.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 319 of 327 in Real Estate, median 55.
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $2.04, with the price 261% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Margin fallingOperating margin −2.6%, average of the prior years 14.1% (to 2024).Profitability 10
- Above fair valuePrice 261% above the fair value of $2.04.Valuation 26
- Loss-makingLoss of $152.14M over the last 12 months.Fundamentals 26
The score is held back by valuation and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 33 to 32.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $1.45 and expensive above $3.39 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $0.83 (cash-flow model) and $3.24 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $1.97, at 7.8% it would be $2.14.
Valuation metrics
Half from the dividend model, half from operating cash flow per share times the median price to cash flow of the REIT industry (14.5). For the fair value, FFO only counts when it is in line with operating cash flow. That is not the case here, for example because the REIT carries its properties at market value, records little depreciation or a gain on sale sits in earnings.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 3.8% on the twelve months before. Revenue has grown solidly since 2006, at about 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −16%, operating −3%, net −19%. Last 12 months: net −10%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 2 Nov 2026EPS reported −$0.21 (expected −$0.15)below expectations
Analyst estimates
- Earnings per share
- −$0.62+1.1%
- Revenue
- $1.47B−0.3%
- Earnings per share
- −$0.38+4.2%
- Revenue
- $1.55B−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Diversified Healthcare Trust
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
327 rated companies in Real Estate
- This company
- 32
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger and next smaller companies by market value
- AedificaAED.BR $6.09B62
- Sabra Health Care REITSBRA $5.49B50
- National Health InvestorsNHI $3.24B61
- LTC PropertiesLTC $2.47B71
- National Healthcare Properties, Inc. (NHP)NHP $1.14B41
- Medical Properties TrustMPT $1.06B40
- Care Property InvestCPINV.BR $603.96M65
- Universal Health Realty Income TrustUHT $542.5M61
ETFs that hold Diversified Healthcare Trust
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS FTSE EPRA Nareit Developed Green UCITS ETF USD disCSYZ | 0.24% | 0.25% | €207.23M |
| State Street SPDR Dow Jones Global Real Estate UCITS ETF (Acc)SPY2 | 0.10% | 0.40% | €52.83M |
| HSBC FTSE EPRA NAREIT Developed UCITS ETFH4ZL | 0.09% | 0.24% | €3.36B |
Show 5 more
| Amundi FTSE EPRA NAREIT Global UCITS ETF Dist10AJ | 0.08% | 0.24% | €603.52M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.35% | €434.1M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.17B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2019)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.